EMAIL THIS PAGE TO A FRIEND

International journal of oncology

Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.


PMID 24805183

Abstract

Evidence in literature has demonstrated that some microRNAs (miRNAs) play a pivotal role in most solid tumor metastasis. Previous studies have showed that miR-100 is downregulated in human prostate cancer tissue compared to normal prostate and also significantly decreased in bone metastatic prostate cancer samples compared with primary prostate cancer. Argonautexa02 (AGO2) is the core effector protein of the miRNA-induced silencing complex and overexpression of AGO2 might enhance tumor metastasis. However, it is unknown whether and how miR-100 and AGO2 regulates metastasis of prostate cancer. Here, we report that miR-100 negatively regulated migration, invasion, epithelial-mesenchymal transition (EMT), colony formation, spheroid formation and expression of the stemness factors c-Myc, Oct4 and Klf4 in PC-3 and DU145 cells. Furthermore, miR-100 expression was negatively correlated with bone metastasis of prostate cancer patients. Notably, luciferase assay showed that AGO2 was a direct target of miR-100. Downregulation of AGO2 repressed migration, invasion, EMT and stemness of prostate cancer cells, and reversed the effects seen with miR-100 downregulation. Downregulation of AGO2 enhanced expression of miR-34a and miR-125b which can suppress migration, invasion, EMT and stemness of cancer cells. Taken together, our findings indicate that loss of miR-100 promotes the metastatic ability of prostate cancer cells at least partially by upregulating AGO2 expression through modulating migration, invasion, EMT and stemness of cancer cells, and suggest that miR-100/AGO2 may play an important role in regulating the metastasis of prostate cancer and is a potential target of prevention and therapy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1405825
Anti-FN1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4502259
Anti-OCT3 antibody produced in rabbit, affinity isolated antibody
AV100956
Anti-POU5F1 antibody produced in rabbit, IgG fraction of antiserum
SAB2101850
Anti-POU5F1 antibody produced in rabbit, affinity isolated antibody
SAB3500316
Anti-POU5F1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701958
Anti-POU5F1 antibody produced in rabbit
SAB2701960
Anti-POU5F1 antibody produced in rabbit
SAB2701972
Anti-POU5F1 antibody produced in rabbit
C7855
Monoclonal Anti-Cdh1 antibody produced in mouse, ~2 mg/mL, clone DCS-266, purified immunoglobulin, buffered aqueous solution
WH0000999M1
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
AMAB90862
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90863
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90865
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution
SAB4700237 Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution
F7387 Monoclonal Anti-Fibronectin antibody produced in mouse, clone FN-15, ascites fluid
F0916 Monoclonal Anti-Fibronectin antibody produced in mouse, clone IST-4, ascites fluid
F0791 Monoclonal Anti-Fibronectin antibody produced in mouse, clone IST-3, ascites fluid